arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

BIOGEN INC.

BIIB
$244.18 ▼ -10.39 (-4.08%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
76 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Neutral
auto_awesome

Analytical Summary

BIOGEN INC. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $36.1B
Dividend Yield —
Revenue Growth 10.6% ↗
Op. Margin None
ROIC None
FCF / Share $4.06 ↗
Trailing P/E —
Price / Book —
FCF Yield 1.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

76-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.80B
↑ +10.6% —
Net Income Profit after all expenses
$-20.60M
↓ -121.1% —
Operating Margin Operating profit as % of sales
24.1%
↓ -15.6% —
FCF / Share Free cash flow per share
$4.06
↑ +47.1% —
Long-Term Debt Long-term obligations
$7.29B
— 0.0% —

Health Breakdown

Profitability ↓
77
Cash Quality ↓
81

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 20 years · 76 quarters